Anti-EGFR monoclonal antibody KSB 107

Drug Profile

Anti-EGFR monoclonal antibody KSB 107

Alternative Names: Chimeric human:sheep monoclonal antibody KSB 107; KSB 102; KSB 107; Monoclonal antibody KSB 107; Project KSB 102

Latest Information Update: 28 Jul 2004

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Xenova Group
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 28 Jul 2004 Discontinued - Preclinical for Solid tumours in United Kingdom (unspecified route)
  • 25 Sep 2003 KS Biomedix Holdings has been acquired by Xenova Group
  • 22 May 2001 Preclinical development for Solid tumours in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top